Background and Purpose-Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dual antiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events. There is a paucity of data, however, on the efficacy or effectiveness of such an approach in the treatment of stroke patients with symptomatic large artery atherosclerotic occlusive disease.
L arge artery atherosclerotic occlusive disease (LAA) is an important cause of ischemic stroke. 1 Severity, recurrence rate, and overall outcome of stroke due to LAA are high and generally worse than other forms of stroke. [2] [3] [4] [5] A mainstay of recurrent stroke prevention has been the administration of aspirin alone or clopidogrel. 6 However, the therapeutic effect on risk reduction has been modest (12%). 7 The modest effect of mono antiplatelet therapy led to the study of combination antiplatelet therapy for recurrent stroke prevention.
Dual antiplatelet therapy was shown to be beneficial for patients with coronary artery disease. 8 Similarly, stroke patients with symptomatic LAA might benefit from such treatment. Several studies including the SPS3 trial (Secondary Prevention of Small Subcortical Stroke) and MATCH trial (Management of Atherothrombosis With Clopidogrel in High-Risk Patients) evaluated dual antiplatelet therapy for recurrent stroke prevention in nonembolic stroke patients. 9, 10 In both SPS3 and MATCH the main results did not support combination therapy over aspirin or clopidogrel, respectively. Although CHANCE (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events) and the POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trials showed that dual antiplatelet therapy might have a benefit in reducing the probability of ischemic events, 11, 12 these studies included all nonembolic ischemic stroke types, and thus, did not restrict enrollees to those patients with symptomatic LAA only.
Because there are a limited number of studies specifically addressing recurrent stroke prevention in symptomatic LAA, [13] [14] [15] [16] [17] large observational data with quasi-experimental design might help to fill this gap. Therefore, we evaluated the effectiveness of the combination of clopidogrel plus aspirin versus aspirin in acute ischemic stroke patients with LAA, using a nationwide, multicenter, and prospective stroke registry data.
Methods
Requests for access to the data used in this report will be considered by the corresponding author.
Study Population
We used a multicenter stroke registry database (the Clinical Research Collaboration for Stroke in Korea), which prospectively enrolled acute ischemic stroke or transient ischemic attack (TIA) patients. 18, 19 The primary purpose of the registry was to describe the epidemiological profiles, care qualities, and outcomes of stroke in Korea. 20, 21 Clinical, laboratory, and radiological data from 15 university and regional tertiary hospitals were collected since 2008 with the financial support of the Korean government.
We identified acute ischemic stroke or TIA patients with symptomatic LAA who were admitted within 7 days from stroke onset and treated with either aspirin only or clopidogrel plus aspirin at admission retrospectively. Those who received antithrombic drugs other than aspirin and clopidogrel were excluded. All cases were confirmed to have a relevant cerebral infarction on diffusion-weighted magnetic resonance imaging. Stroke cause was classified according to a modified version of the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria. 22, 23 We excluded the following patients who (1) were suspected to have branch atheromatous disease based on morphological characteristics on MRI and no steno-occlusion on magnetic resonance angiography or computerized tomographic angiography, 24 (2) had a high-risk cardioembolic source, and (3) were treated with antiplatelet agents other than clopidogrel plus aspirin or aspirin only. Treatment compliance was measured using 6-item modified Morisky Medication Adherence Scale at 3 months after a qualifying stroke event, and high adherence was defined as motivation and knowledge domain scores ≥2.
Collection of information for the Clinical Research Collaboration for Stroke in Korea registry was approved by the local institutional review boards in all participating centers with a waiver of patient consent because of anonymity and minimal risk to participants. We obtained institutional review board approval for the use of the registry database for this study additionally.
Data Collection
Patients included in the study received either (1) aspirin only or (2) clopidogrel plus aspirin at admission. Since there were cases with a discrepancy between the medication at admission and discharge, we defined study populations as follows to delineate the genuine effect of antiplatelet treatment; intention-to-treat (ITT), per-protocol (PP), and as-treated (AT) populations (Figure 1 ). The ITT population was defined by antiplatelet treatment at admission regardless of medication at discharge. The PP population was restricted to the population who survived during hospitalization and received the same medication at admission and at discharge. In the AT population, censoring occurred at the time of medication change if this change occurred during hospitalization, and reenrollment of these patients was allowed at discharge according to the discharge medication. The maintenance dose of aspirin and clopidogrel was 100 and 75 mg, respectively.
The following demographic, clinical, imaging, and laboratory data were collected prospectively: (1) age and sex; (2) medical history including hypertension, diabetes mellitus, dyslipidemia, smoking, coronary heart disease, and past stroke; (3) medication history such as antiplatelet, anticoagulant, and lipid-lowering agents; (4) estimation of prehospitalization modified Rankin Scale and stroke severity at acute presentation measured by the National Institutes of Health Stroke Scale; (5) stroke subtypes according to a modified TOAST criteria; (6) systolic and diastolic blood pressure, white blood cell count, platelet count, fasting glucose level, and low-density lipoprotein-cholesterol level; (7) brain MRI results; (8) degree of steno-occlusion of relevant vessels classified into <50%, ≥50%, or total occlusion; and (9) antithrombotic agents at admission and at discharge.
Outcome Assessment
All registered stroke patients were prospectively followed during hospitalization and after discharge up to 1 year after index stroke. During hospitalization, early neurological deteriorations including stroke recurrence and vascular death were captured by both treating physicians and research coordinators, and all the registered cases were checked weekly. At 3 months and 1 year after qualifying stroke event, study coordinators at each center captured outcome events by reviews of medical records based on a predefined outcome capture protocol and telephone/direct interviews with patients or their caregivers using structured questionnaires. Yearly workshops were held to train investigators and study coordinators, and monthly audits were performed to check the integrity of the database. Details of the outcome event capture process are described elsewhere. 20, 21 We collected outcome events up to 1 year after the index stroke and permitted a 3-month grace period. The primary end point was the composite outcome of stroke recurrence, myocardial infarction (MI), and all-cause death. The secondary end point was recurrent stroke or all-cause death.
We defined recurrent stroke as sudden development of a new neurological deficit or worsening of an existing symptom, lasting >24 hours after the index stroke event, if there are attributable lesions on computed tomography or MRI. Stroke events included both ischemic and hemorrhagic stroke.
Statistical Analysis
Since the number of patients were different among the ITT, PP, and AT groups, all analyses were done separately according to study population. For missing values, single imputations were done by probabilistic sampling or group median for categorical or continuous values, respectively. Baseline characteristics were compared between aspirin and clopidogrel-aspirin groups using the Student t test for continuous variables or Pearson χ 2 test for categorical variables. A multivariable Cox frailty model with random intercepts was used to account for center clustering. It was assumed that patients who had higher risk of stroke recurrence would be more likely to receive combinatorial medication compared with low-risk patients. Therefore, propensity scores and stabilized inverse probability of treatment weighting (IPTW) were used to balance possible baseline differences between treatment groups. To calculate a propensity score, a multiple logistic regression model was used as shown in the Table. An absolute standardized difference was calculated before and after applying the stabilized IPTW to check remaining imbalances between study groups. Variables with absolute standardized difference >0.1 after applying the stabilized IPTW were included in the frailty model. Along with the frailty analysis, crude and multivariable Cox regression models (Table) were also performed. To check the robustness of the treatment effect, the ITT patients who arrived within 24 hours after stroke onset were separately analyzed to reflect recent clinical trials (FASTER [Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence], CHANCE, and POINT trial) as sensitivity analyses. 11, 12, 25 In addition, a sensitivity analysis on the ITT population excluding patients treated with carotid endarterectomy or stenting was done. We also checked inclusion of patients with event outcomes during hospitalization into PP population can change the result.
All the study populations and outcome measures were predefined before institutional review board approvals, and all the analyses were performed as planned. Significance levels were set at a 2-tailed P<0.05. Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
Results
A total of 5934 patients with symptomatic LAA received either clopidogrel plus aspirin (n=2903, 49%) or aspirin alone (n=3031, 51%) and were included in the ITT population ( Figure 1 ). Of these, 3689 (62%) patients continued the same medication until discharge and were considered as the PP population. Patients who switched to the other treatment group (aspirin to clopidogrel-aspirin, n=802 and clopidogrelaspirin to aspirin, n=119) without reaching an outcome end point during admission were reenrolled and included in the AT population (primary outcome AT population, n=6893). The frequency of missing values was 290 cells (0.2%; Table I in the online-only Data Supplement).
The median follow-up duration was 369 days (interquartile range, 361-386 days). Among 4849 (82%) patients who were able to obtain the medication adherence information at 3 months after index stroke event, 3929 (81%) reported high adherence. Among LAA stroke patients in ITT population, 12.1% (n=353) of 2903 patients in the clopidogrelaspirin group had an event of recurrent stroke, MI, or death, whereas 13.5% (n=410) of 3031 patients in the aspirin group had an event. In the PP population, 8.9% (n=197) of 2209 patients in the clopidogrel-aspirin group and 10.9% (n=162) of 1480 patients in the aspirin group had an event. In the AT population, 9.8% (n=362) of 3705 patients in the clopidogrel-aspirin group and 8.5% (n=268) of 3150 patients in the aspirin group had an occurrence of stroke, MI, or death. Table II in the online-only Data Supplement shows the outcomes in each group.
As expected, comparisons of treatment groups in the ITT population before stabilizing the IPTW showed that the clopidogrel-aspirin group had a higher risk for outcome events. They were more likely to be male, have hypertension, diabetes mellitus, dyslipidemia, coronary artery disease or previous MI, previous history of stroke or TIA, higher fasting glucose level, higher National Institutes of Health Stroke Scale at admission, and more severe relevant vessel steno-occlusion (Table) . Along with antithrombotic therapy, the clopidogrelaspirin group compared with the aspirin group, tended to receive more intensive treatment, such as intra-arterial thrombolysis and statin therapy. The PP and AT populations showed similar results (Tables III and IV in the online-only Data Supplement). After applying the stabilized IPTW, all baseline variables were well balanced (absolute standardized difference <0.1; Figure 2 for the ITT analysis and Figure I in the online-only Data Supplement for PP and AT analysis).
On the crude analysis (Figure 3) , compared with aspirin, clopidogrel plus aspirin did not decrease the hazards of a primary outcome in the ITT analysis, but did in the PP and AT analyses (ITT population: hazard ratio (HR), 0. Figure 4 shows Kaplan-Meier curves after applying the stabilized IPTW for patients treated with clopidogrel plus aspirin or aspirin only. When we further divided the causes of death, the main difference was death due to stroke or unknown cause (Table V in the online-only Data Supplement) rather than nonvascular cause.
In sensitivity analysis, the ITT patients who arrived within 24 hours had further reduced hazards of the primary outcome and all-cause death when treated with clopidogrel plus aspirin (for the primary outcome: HR, 0.77; 95% CI, 0.64-0.93; P=0.008; Figures I through III in the online-only Data Supplement). Exclusion of patients who treated with carotid endarterectomy or stenting showed similar, but weaker trends. When we added patients with event outcomes during hospitalization into PP population, the result was also comparable (for the primary outcome: HR, 0.73; 95% CI, 0.61-0.87; P=0.0004). Stroke recurrence was not different between clopidogrel-aspirin and aspirin alone groups in all the sensitivity analysis populations. Figure 2 . Absolute standardized differences for estimating propensity score before and after inverse propensity score weighting in intentionto-treat (ITT) subjects (also see Figure I in the online-only Data Supplement for per-protocol and as-treated population). IPTW indicates inverse probability of treatment weighting; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack; and WBC, white blood cell.
Discussion
In this study, we tested the effectiveness of dual antiplatelet treatment compared with mono antiplatelet treatment using a multicenter, prospective stroke registry database. We found that acute ischemic stroke patients with symptomatic LAA receiving clopidogrel plus aspirin might have lower risk of the composite of recurrent stroke, MI and death, compared with those receiving aspirin alone, during the first year after stroke and this observation was mainly attributable to overall mortality reduction by dual antiplatelet treatment.
Although dual antiplatelet therapy is highly recommended for coronary artery disease, 8 indications for dual antiplatelet therapy for noncardioembolic stroke patients have become better defined. Considering LAA patients are at higher risk of stroke recurrence than stroke patients with the small-vessel disease, 2,26 these patients could benefit from intensive antiplatelet therapy by possibly limiting generation of thrombi on the atherosclerotic plaque wall. It has been shown that dual antiplatelet therapy can decrease microembolic signals as detected by transcranial Doppler ultrasound in patients with cerebral or carotid artery stenosis. 13, 14, 27 Current guidelines indicate that short-term dual antiplatelet treatment may be used early after cerebral ischemia after minor nonembolic stroke or TIA based on evidence from the CHANCE trial. 6, 12 The aforementioned recommendation is further supported by the results of POINT. 11 However, the CHANCE and POINT results are not necessarily generalizable to LAA stroke patients since they usually have more severe neurological symptoms than other nonembolic stroke patients, and CHANCE and POINT did not focus exclusively on patients with LAA.
The risk of stroke recurrence in our study was not different between dual antiplatelet therapy versus monotherapy. Similarly, the COMPRESS (Combination of Clopidogrel and Aspirin for Prevention of Recurrence in Acute Atherothrombotic Stroke Study) showed that aspirin plus clopidogrel treatment for 30 days in acute atherosclerotic stroke patients did not reduce the risk of new ischemic lesions on MRI or clinical stroke recurrence. 16 In our study, dual antiplatelet treatment was frequently administered to patients with a higher risk profile and worse initial neurological deficits on presentation. Although dual antiplatelet therapy did not differ from single antiplatelet therapy in reducing stroke recurrence, the finding might be explained by more prevalent risk factors in the dual antiplatelet treatment group.
A benefit of dual antiplatelet therapy in all-cause death was an unexpected result since patients who were treated with clopidogrel and aspirin were more likely to have prognostic factors for a worse outcome. In detail, death due to stroke and unknown cause was decreased in the clopidogrel plus aspirin Table. Frailty model with stabilized inverse probability of treatment weighting (IPTW) was adjusted for age, previous history stroke or transient ischemic attack (TIA), and in-hospital treatment with statin in the ITT and AT population. In PP population, fasting glucose level was also added in frailty model. group. We have no explanation for the decrease in death due to unknown cause. Therefore, we could not exclude the possibility that patients with frailty or poor prognostic conditions for whom physicians in charge hesitated to use dual antiplatelet agents more frequently belonged to the aspirin alone group.
During hospitalization, 26% of the aspirin only group changed their medication to clopidogrel plus aspirin, whereas 4% of the clopidogrel-aspirin group changed their medication to aspirin monotherapy. At the time of discharge, 51% of patients were on clopidogrel plus aspirin, whereas only 27% were on aspirin monotherapy. This finding might be explained as a result of etiologic diagnostic study during hospitalization as patients diagnosed with LAA were considered to be highrisk patients. 4 In our study, 26% of patients had already been prescribed antithrombic agents before the index ischemic stroke. This also may partially explain a high percentage of dual antiplatelet therapy administration in our study, because patients who had stroke while on aspirin, so-called aspirin failure, might benefit from changing antiplatelet strategies from aspirin only to clopidogrel plus aspirin. 18 Similarly, in a recent multicenter international study of TIA or minor stroke population, 13.4% of patients were taking dual antiplatelet therapy at the time of discharge. 26 As our study shows, many patients changed their medication during hospitalization. To avoid overestimation of the effect of clopidogrel plus aspirin over aspirin only, we incorporated an analysis model to include ITT, PP, and AT analyses similar to that in randomized controlled trials. Since the ITT population comprised some patients who had switched or stopped their medication during hospitalization, the effect might be underestimated compared with that in the PP or AT populations. Indeed, a treatment effect was evident in the PP and AT populations, whereas it was only marginal in the ITT population. Thus, PP and AT analyses in this circumstance might be more representative analysis, since treatment strategies could change during hospitalization.
Our study has several limitations. First, the area of LAA disease is still broad and heterogeneous, such as the location of steno-occlusion, infarct burden which might affect the risk of bleeding, stroke severity, and underlying risk factors might interact with antiplatelet treatment. Furthermore, there may be errors in stroke subtype diagnosis leading to inclusion of non-LAA cases and excluding patients without diffusion-weighted magnetic resonance imaging might cause selection bias. However, we attempted to correctly classify stroke subtype by using the MRI-based algorithm for ischemic stroke subtype classification. 23 In our study, only 260 patients (4%) were excluded due to the lack of diffusion-weighted magnetic resonance imaging despite meeting all other criteria (Table VI in the onlineonly Data Supplement). Second, since statin is an effective therapy for both primary and secondary prevention, we incorporated prestroke and poststroke statin in our propensity model. But we could not exclude possible unmeasured confounding related to statin dosage, 28 ,29 which we were not able to collect. Third, although we checked drug compliance using 6-item Morisky Medication Adherence Scale by telephone interview, we could not fully track the exact course of antiplatelet treatment in all cases. Fourth, missing value imputation could bias the treatment effect. Fifth, as our outcome capture process was done by telephone interview with patients or their caregivers, the direct cause of death might not be able to be fully tracked. Finally, since this is a nonrandomized, retrospective, observational, and registry-based study, baseline patient characteristic imbalances or residual confounding might affect the results. Therefore, our study should be cautiously interpreted, and further randomized trials which focus on LAA patients should be considered.
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